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Abstract 32 
The rapid identification of antimicrobial resistance is essential for effective treatment 33 
of highly resistant Mycobacterium tuberculosis (M. tb). Whole genome sequencing 34 
provides comprehensive data on resistance mutations and strain typing for 35 
monitoring transmission, but unlike conventional molecular tests, this has only 36 
previously been achievable from cultured M. tb. Here we describe a method utilising 37 
biotinylated RNA baits, designed specifically for M. tb DNA to capture full M. tb 38 
genomes directly from infected sputum samples, allowing whole genome sequencing 39 
without the requirement of culture. This was carried out on 24 smear-positive sputum 40 
samples, collected from the UK and Lithuania where a matched culture sample was 41 
available, and two samplesthat had failed to grow in culture. M. tb sequencing data 42 
was obtained directly from all 24 smear-positive culture-positive sputa, of which 20 43 
were high quality (>20x depth and >90% of genome covered). Results were 44 
compared with conventional molecular and culture-based methods, and high levels 45 
of concordance were observed between phenotypical resistance and predicted 46 
resistance based on genotype. High quality sequence data was obtained from one 47 
smear positive culture negative case. This study demonstrates for the first time, the 48 
successful and accurate sequencing of M. tb genomes directly from uncultured 49 
sputa. Identification of known resistance mutations within a week of sample receipt 50 
offers the prospect for personalised, rather than empirical, treatment of drug resistant 51 
tuberculosis, including the use of antimicrobial-sparing regimens, leading to 52 
improved outcomes. 53 
 54 
 55 
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 60 
Introduction 61 
The global incidence of multi, extensively and totally drug resistant tuberculosis has 62 
risen over the last decade (1), making it increasingly important to rapidly and 63 
accurately detect resistance. The gold standard for antimicrobial resistance testing 64 
relies on bacterial culture, which for M. tb can take upwards of several weeks. 65 
Molecular tests, such as the Xpert (MTB/RIF) and line probe assays, which can be 66 
used directly on sputum have improved identification of multi-drug resistant (MDR) 67 
M.tb but are only able to identify limited numbers of specific resistance mutations (2, 68 
3). 69 
Whole bacterial genome sequencing (WGS) allows simultaneous identification of all 70 
known resistance mutations as well as markers with which transmission can be 71 
monitored (4). WGS of M.tb provides superior resolution over other current methods 72 
such as spoligotyping and MIRU-VNTR for strain genotyping (5) and its usefulness in 73 
defining outbreaks has been demonstrated (6-9). Currently however, WGS of M. tb 74 
requires prior bacterial enrichment by culturing and therefore most outbreak studies 75 
have been retrospective (6-8). Recently WGS of M. tb has been achieved from 76 
three-day old MGIT (Mycobacterial growth indicator tube) culture, thus reducing the 77 
time from sample receipt to resistance testing to less than a week (10). However, 78 
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with the mean time to positive MGIT culture being 14 days (11, 12), most WGS 79 
results will not be available for more than two weeks, which is too long a delay 80 
before starting therapy. Moreover, the extent to which even limited culture perturbs 81 
the original sample composition remains unknown, especially in cases where a 82 
patient is suffering from infection with multiple strains, a common occurrence in 83 
developing countries where it has been observed in up to 19% of cases (13). As 84 
described here we utilised the oligonucleotide enrichment technology SureSelectXT 85 
(Agilent) method to obtain the first M. tb genome sequences directly from both smear 86 
positive and smear negative sputum.  87 
 88 
Methods 89 
Samples 90 
A total of 58 routine diagnostic samples from the UK and Lithuania, including 24 91 
smear-positive sputum specimens from pulmonary TB patients and 24 matching 92 
cultures (grown on Middlebrook 7H11 plates from the relevant sputum specimens, 93 
see below), and 10 sputum samples from patients who had previously been 94 
diagnosed with TB and which failed to grow in culture, were analysed. Further details 95 
can be found in supplementary table 1. Sputum was visually scored as 1+ to 3+ for 96 
acid fast bacilli (AFBs). Sequencing and subsequent analysis were processed blind 97 
with respect to smear and resistance results. 98 
Bacteriological methods  99 
Prior to treatment, all sputum specimens were kept frozen at -20 ˚C. Bacteriological 100 
culture samples were processed as follows. Samples were decontaminated using N-101 
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acetyl-L-cysteine/NAOH (1% NaOH final concentration) and re-suspended after 102 
centrifugation in 2 mL phosphate buffer (pH 6.8). Subsequently, 0.1 ml of the 103 
suspension was used for inoculation onto Middlebrook 7H11 media while the 104 
remaining suspension was used for the genomic DNA extraction directly from 105 
sputum (see below). Plates were incubated at 37 ˚C for at least four weeks or until 106 
visible growth was obtained. 107 
DNA extraction from sputum 108 
The bacterial suspension used for inoculation was re-pelleted by centrifugation at 109 
16,000 g. Supernatants were decanted, and pelleted cells re-suspended in 0.3 mL  110 
Tris-EDTA (TE), buffer and transferred to sterile 2 mL screw caps tubes containing 111 
~250 µL 0.1 mm glass beads (Becton Dickinson). Microorganisms were heat killed at 112 
80˚C for 50 minutes and then frozen at -20˚C; after thawing the tubes were vortexed 113 
for three minutes and centrifuged for five minutes at 16,000 g. The supernatant was 114 
transferred to a clean 2mL tube for subsequent DNA purification using the DNeasy 115 
Blood and Tissue DNA extraction Kit (Qiagen) as per manufacturer’s instructions. 116 
Genome copies were measured in the sputum samples using the Artus® M. 117 
tuberculosis RG PCR Kit (Qiagen), as per manufacturer’s instructions. 118 
DNA extraction from cultures 119 
Two loopfuls of M.tb growth from Middlebrook 7H11 plates were transferred into 2 120 
mL screw caps tubes containing ~250 µL of 0.1mm glass beads (Becton Dickinson) 121 
and 0.3 mL TE buffer. Subsequent processing, genomic DNA extraction and 122 
purification were done as described for the sputum samples.  123 
Resistance profiling  124 
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All isolates were tested for susceptibility to first line drugs rifampicin (RIF), isoniazid 125 
(INH), ethambutol (EMB), pyrazinamide (PZA), and streptomycin (STR). Isolates 126 
resistant to at least RIF and INH (i.e. multidrug resistant, MDR-TB) were additionally 127 
tested for susceptibility to kanamycin (KAN), amikacin (Amk), ofloxacin (OFL), 128 
capreomycin (CAP), ethionamide (ETH), prothionamide (PTH), and par-129 
aminoasalicylate sodium (PAS). 130 
 131 
Drug susceptibility testing (DST) was carried out on an automated liquid media-132 
based system Bactec MGIT960 (Becton Dickinson) using standard drug 133 
concentrations (in micrograms per millilitre) as follows: STR 1.0; INH 0.1; RIF 1.0; 134 
EMB 5.0; PZA 100.0; OFL 2.0; Amk 1.0; CAP 2.5; KAN 5.0; ETH 5.0; PTH 2.5; and 135 
PAS 4.0.(14)  136 
Spoligotyping  137 
Spoligotyping was carried out as described previously using membranes with 138 
immobilised oligonucleotide probes (Ocimum Biosolutions) (15). For identification of 139 
genetic families and lineages, 43-digit binary spoligotyping codes were entered into 140 
MIRU-VNTRplus database (www.miru-vntrplus.org) and families identified using 141 
similarity search algorithm. 142 
SureSelectXT Target Enrichment: RNA baits design 143 
120-mer RNA baits spanning the length of the positive strand of H37Rv M. tb 144 
reference genome (AL123456.3),(16) were designed using an in-house Perl script 145 
developed by the PATHSEEK consortium. The specificity of the baits was verified by 146 
BLASTn searches against the Human Genomic + Transcript database. The custom 147 
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designed M. tuberculosis bait library was uploaded to SureDesign and synthesised 148 
by Agilent Technologies. 149 
 150 
SureSelectXT Target Enrichment: Library preparation, hybridisation and Illumina 151 
sequencing. 152 
Prior to processing M.tb DNA samples were quantified and carrier human genomic 153 
DNA (Promega) was added to obtain a total of 3 µg DNA input for library preparation. 154 
All DNA samples were sheared for 4x60 seconds using a Covaris S2 (duty cycle 155 
10%, intensity 4 and 200 cycles per burst using frequency sweeping). The samples 156 
were then subjected to library preparation using the SureSelectXT Target Enrichment 157 
System for Illumina Paired-End Sequencing Library protocol (V1.4.1 Sept 2012). 158 
Prior to hybridisation eight cycles of pre-capture PCR was used, and ~750 ng of 159 
amplified product was included in each hybridisation (24 hours, 65 ˚C). 16 cycles of 160 
post capture PCR was performed, with indexing primers. The resulting library was 161 
run on a MiSeq (Illumina) using a 600bp reagent kit, typically in pools of 8 or 10, 162 
some sputum smear positive 1+ samples were run in smaller pools to increase 163 
coverage. Base calling and sample demultiplexing were generated as standard on 164 
the MiSeq machine producing paired FASTQ files for each sample. The raw 165 
sequencing data has been deposited on the European Nucleotide archive (upon 166 
acceptance of publication). An overview of the process is presented in 167 
Supplementary figure 1. 168 
Sequence Analysis  169 
The samples were analysed using a reference based mapping approach 170 
implemented in CLC Genomics workbench (v. 7.5). Prior to mapping the reads were 171 
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trimmed to remove low quality sequence at the end of reads or adaptor 172 
contamination. The reads were mapped against the H37Rv genome (AL123456.3) 173 
using default parameters with the addition of  a similarity  threshold to remove non-174 
M.tb reads, by which any reads where at least 90% of the length does not match the 175 
reference by at least 90% were discarded. This was required to remove non-M.tb 176 
reads. Duplicate reads were then removed from the mapped reads, and the average 177 
depth of coverage calculated. The percentage of on-target reads (OTR) was 178 
calculated by counting the number of reads that were successfully mapped to 179 
H37Rv. Any reads that did not map were assumed to be off-target (not M.tb). 180 
Bases were called using VarScan (v 2.3.7),(17) applying high stringency parameters 181 
including a minimum depth of 4 reads, a minimum average quality of 20, a p value 182 
cutoff of 99e-02  and an absence of heterozygosity at a level greater than 10%. A 183 
consensus sequence was generated where only called bases were considered, and 184 
any bases which failed quality thresholds were called as Ns. To build the phylogeny 185 
any variants which were identified in IS elements or the PE, PPE gene families were 186 
excluded, as these regions are recognized to be prone to false positive SNP calls.(8) 187 
The remaining positions (representing 92% of the genome) were then used to build a 188 
maximum likelihood tree using RAxML v 8.0.0(18) with 100 bootstrap replicates. 189 
Genome coverage was calculated by dividing the number of high quality bases 190 
successfully called (as per VarScan above) by the reference genome (H37Rv) size. 191 
Depth of coverage refers to the number of reads supporting a position.  192 
Calling genotypic resistance 193 
Potential drug susceptibility associated variants were detected using a custom Perl 194 
script using positions identified in a curated drug resistance database 195 
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(http://pathogenseq.lshtm.ac.uk/rapiddrdata) (19) from bam and bcf files (20). 196 
Variants were considered if they were supported by at least 2 forward and reverse 197 
reads, had p values of at least 0.05 for strand bias, and 0.001 for read end bias, 198 
base quality bias and mapping quality bias as calculated by bcftools (20). A sample 199 
was called as genotypically resistant if it had a mutation in over 10% of reads. Any 200 
mutation identified in the ribosomal RNA genes were inspected manually to exclude 201 
any that may be the result of off-target enrichment of these highly conserved regions. 202 
Those that were found on reads that formed distinct haplotypes, where variants were 203 
found in close association with other variants on multiple reads were excluded as 204 
they likely belonged to non-M. tb species.  205 
The analysis was also carried out independently on a customized version of the CLC 206 
Genomics Workbench (QIAGEN-AAR), which facilitates a fully-automated pipeline 207 
including the steps of trimming, mapping to reference, removal of duplicate mapped 208 
reads, variant calling and cross-referencing with the resistance database (described 209 
above). Variants called using the automated workflow (using the Low Frequency 210 
Variant Detector, CLC Genomic Workbench), were considered significant if the 211 
average quality was above 30, a frequency greater than 10% and the forward and 212 
reverse read balance was above 0.35. Variants were inspected manually for possible 213 
contamination. The runtime when using a standard laptop (Macbook Pro) was on 214 
average 1h per sample. The resistance genotypes called were in agreement with 215 
those identified using the workflow described above 216 
 217 
Results 218 
 219 
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Successful enrichment directly from sputum in both smear positive and negative 220 
tuberculosis cases 221 
To assess the potential benefits of enrichment strategies for WGS of clinical M. tb, 222 
we compared the percentage of on-target reads (%OTR), as defined in the methods, 223 
and the mean sequencing depth) for two sputum samples, each processed with and 224 
without enrichment. The average %OTR for M. tb sequenced directly (no-225 
enrichment) from sputum was 0.3%, with 4.6x sequencing depth, compared to with 226 
enrichment which generated a %OTR of 82%, with a mean depth of 200x (Figure 1). 227 
Although cultured M. tb sequenced well with and without enrichment, the former 228 
gave greater mean read depth (Supplementary Figure 2). Even coverage across the 229 
genome was obtained with no bias observed for particular regions or genes 230 
(Supplementary figure 3).   231 
Over 98% of the M. tb genome was recovered from 20 of 24 (83%) smear-positive 232 
culture-positive sputa. Fully complete genomes are not achievable for M. tb using 233 
short-read sequencing technology, due to the difficulties presented by repetitive 234 
regions and the PE and PPE genes (8, 21). Similar levels of genome coverage and 235 
sequencing depth were also obtained from the non-enriched matched cultures 236 
(Figure 2a). The depth of coverage obtained for four sputum samples was poor 237 
(MTB-41: 9x, MTB-42: 14x, MTB-43: 6x and MTB-44: 11x) resulting in a genome 238 
coverage of less than 90%.  In the case of MTB-43 and MTB-44, which had an input 239 
of 1 and <1 genome copies per µl respectively, (these values are out of range of 240 
reliable standards as measured by real-time PCR) this is likely to be due to a low 241 
pathogen load.  242 
11 
 
In addition, we were able to enrich and sequence M.tb from two smear-positive but 243 
culture negative sputum samples (MTB-69 and MTB-73), successfully recovering 244 
sequence data from the former with a sequence depth of 8.5x (Figure 2B). We also 245 
attempted to sequence eight culture-negative smear-negative sputum samples, 246 
which were obtained from previously diagnosed patients (MTB-67-72 and MTB-74 -247 
76). Surprisingly, for two of these samples, MTB-68 and MTB-76, we obtained high 248 
quality M. tb sequence data with an average depth of coverage of 9x and 22x, 249 
respectively (Figure 2b). For five of the samples we detected low numbers of M.tb 250 
reads (<1x depth of coverage), which may represent a very low load or residual DNA 251 
from dead bacilli. No full length M. tb reads were detected in the final sample (MTB-252 
72).   253 
Concordance between genotypes obtained from culture and sputa matched pairs 254 
Using the high quality variable sites called we constructed a maximum likelihood 255 
phylogenetic tree. Six samples, with less than 90% genome and SNP position 256 
coverage, had an unusual phylogenetic positioning, close to nodes on the tree 257 
(Supplementary figure 4), a pattern consistent with a lack of informative sites. With 258 
these samples excluded, the resulting robust phylogeny revealed that for all of the 259 
matched pairs an identical or near-identical genome was obtained from culture and 260 
sputa (Supplementary figure 5).  261 
Concordance between resistance phenotype and genotype 262 
For the 24 matched pairs we sought to identify the genetic resistance determinants 263 
which could explain their antibiotic susceptibility profile. Predicted resistance 264 
mutations were 100% concordant between sequences obtained from culture and 265 
sputa (Table 1), with the exception of the low coverage samples (MTB-41, MTB-42, 266 
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MTB-43 and MTB-44) for which we were unable to confidently call variants at many 267 
of the targeted loci.  268 
The predicted resistance genotype agreed well with the phenotypic resistance 269 
profiles, with a possible resistance conferring mutation being detected in 88% 270 
(59/67) of phenotypically resistant cases, and no known resistance mutation in 94% 271 
(72/77) of sensitive cases. Two phenotypically pyrazinamide resistant cases 272 
(isolated from Patients 7 and 14) both belonging to the URAL lineage were identified 273 
as having a large chromosomal deletion (8.64kb) resulting in the removal of the pncA 274 
gene, the activator of the pro-drug pyrazinamide, plus ten surrounding genes 275 
(Supplementary figure 6).  276 
Four samples were phenotypically ethambutol sensitive but had a mutation in codon 277 
306 of the embB gene.  This mutation has been observed to cause both low and 278 
high level resistance to ethambutol, so may lead to a borderline phenotype (22, 23). 279 
Patient 15’s isolate was phenotypically ethambutol sensitive but had a Q497R 280 
mutation in the embB gene, which has previously been associated with being 281 
sensitive in both clinical isolates (24) and through the construction of isogenic 282 
mutants (25) so was discounted.  Similarly patient 2’s isolate was phenotypically 283 
sensitive to isoniazid, but had a G269S mutation in the kasA gene, which has also 284 
previously been found in sensitive isolates (26). Patient 5’s isolate was also 285 
phenotypically sensitive to rifampicin notwithstanding a L452P (codon 533 in E. coli) 286 
mutation in the rpoB gene.  This mutation  has also been associated with both high 287 
and low rifampicin resistance in the literature (27). M. tb isolated from this patient in 288 
the past had been found to be rifampicin resistant suggesting that either this 289 
mutation results in a borderline phenotype.  Alternatively, a mixture of rifampicin 290 
resistant and sensitive strains could have been present in this patient, although this 291 
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was not detected in the sequencing data obtained from either the sputum or culture. 292 
The remaining eight samples were phenotypically resistant, with an absence of any 293 
described or speculative causative genetic mutations. Five of these were 294 
phenotypically resistant to second-line drugs for which the genetic basis of 295 
resistance is less well understood. These discrepancies highlight that the current 296 
limitation on our ability to detect resistance via whole genome sequencing is not the 297 
detection itself, but rather lack of data on the genetic correlates of resistance. 298 
Any alleles detected at a low level (<10%), were excluded from this analysis due to 299 
the potential problem of carry-over on the sequencing platform which has been 300 
previously described (28).  Further work will be required to quantify the validity of 301 
these mutations, or to assess their clinical significance. In the majority of cases, 302 
resistance alleles had reached fixation or near-fixation in both culture and sputa 303 
samples, as they were found in 98-100% of the reads. In patient 10 however, 304 
significant heterozygosity was detected, with more than one allele being detected at 305 
greater than 10% at a single position.  A mixture of three different resistance alleles 306 
and one sensitive allele were detected within a single codon of the gyrA gene (Figure 307 
3). Remarkably almost identical proportions were detected in the corresponding 308 
culture sample.  309 
 310 
 311 
Discussion 312 
Whole genome sequencing of bacteria has been shown to provide comprehensive 313 
data on antimicrobial resistance, which could be used to inform antimicrobial 314 
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prescribing. However current methods which rely on culturing the organism prior to 315 
sequencing are slow and so of limited use in patient management. As a result initial 316 
antimicrobial prescribing for resistant M. tb, remains largely empirical in the early 317 
phase of treatment.  Currently MDR M. tb can be diagnosed rapidly on the Xpert 318 
MTB/RIF system, but a rapid test for extensively drug resistant (XDR) cases is 319 
unavailable. As Xpert (MTB/RIF) focuses only on rpoB (RIF) mutations unusual 320 
resistance patterns where strains are rifampicin sensitive but show other resistance, 321 
such as the isoniazid resistant, rifampicin sensitive case included in this study, are 322 
missed. Here, we describe the recovery and sequencing of near-complete genomes 323 
directly from 81% (21/26) of smear positive sputa, including those staining for low 324 
numbers (+1) of Acid Fast Bacilli (AFBs), within a timescale (up to 96 hours) that 325 
could allow personalised antimicrobial treatment for both sensitive and resistant 326 
cases, including XDR TB. 327 
M. tb is particularly appropriate for the use of diagnostic WGS with enrichment, as, 328 
unlike the majority of pathogenic organisms, M. tb has a well characterised clonal 329 
nature, with relatively low levels of sequence variation and does not undergo 330 
recombination or horizontal transfer (29), thus a stable set of oligonucleotide baits 331 
can be created and sequence data can be mapped against a reference genome. We 332 
have demonstrated that enrichment of M. tb provides sequencing data that matches 333 
the quality and quantity of data obtained via sequencing from culture. Moreover, we 334 
were able to recover high quality M. tb sequencing data from one smear-positive and 335 
one smear-negative case, both from cases who had received anti-TB therapy and 336 
which both failed to grow in culture. However without further clinical information it is 337 
difficult to interpret these cases. Smear-positive culture-negative cases are most 338 
commonly thought to be due to the on-going persistence of dead bacilli in sputum 339 
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samples (30). For this reason, previously treated cases are currently not 340 
recommended for use on PCR-based diagnostic systems such as Xpert, that cannot 341 
distinguish between dead or live bacilli.  Further investigation will be required to 342 
assess the suitability of targeted enrichment in the context of different clinical 343 
scenarios.  There were four smear-positive culture-positive cases where less optimal 344 
data were obtained from sputa, although we envisage that sequencing of such low 345 
titre samples could be improved through further optimization or increased 346 
sequencing depth. It is worth noting these samples were deemed failures based on 347 
commonly used SNP calling thresholds employed by others in the field. Further work 348 
will be required to robustly establish parameters that are sufficient for clinical use 349 
and interpretation, particularly when considering low frequency variants. 350 
Sequencing directly from the clinical sample may reduce any possible biases 351 
associated with culture. The overall presence of hetero-resistance in this study was 352 
low (one patient), with most resistance conferring mutations observed as close to 353 
fixation, i.e. the entire sampled population is resistant.  However, in endemic settings 354 
mixed infections have been observed to be much more prevalent especially in HIV 355 
positive patients (14, 31-33). The detection of these hetero-resistant cases is not 356 
only important for our understanding of how resistance evolves, but could impact on 357 
clinical management (34). Further studies are required to explore any bias on 358 
genetic diversity that may be introduced by culture, particularly in the context of 359 
mixed-strain infections. 360 
A disadvantage of the approach presented here is that it is relatively expensive: 361 
currently costing approximately $350 (USD) per sample in our laboratory. It also 362 
requires skills and machinery currently not available in most microbiological 363 
laboratories. An alternative and cheaper rapid sequence based approach would be 364 
16 
 
to deep sequence total DNA from sputa samples without enrichment.. A recent study 365 
found they could recover M. tb reads from eight smear and culture positive samples 366 
(35). However, in agreement with our study, they obtained a very low depth of 367 
coverage (<1x) in the absence of enrichment, so the usefulness of this approach is 368 
likely to be limited to detection, and is unlikely to provide the detailed genotype and 369 
resistance information that is presented here in a high-throughput manner.  370 
In summary, we have demonstrated whole M. tb genome sequencing directly from 371 
smear positive, culture positive sputa within a clinically relevant time frame that 372 
would enable pro-active patient management.  The quality of sequence data allowed 373 
us to accurately call mutations that are known to be associated with resistance to 374 
first and second line drugs. Furthermore, excluding the need for culture affords new 375 
opportunities for biological insights into the evolution of M. tb antimicrobial resistance 376 
and within-patient evolution. 377 
 378 
Figures 379 
Figure 1: Mean coverage and percentage of on target reads (OTR) when sequencing 380 
from sputum with and without enrichment for two samples 381 
Figure 2: (A) Depth of coverage obtained for smear positive samples from sputum 382 
and culture. (B) Depth of coverage for sputum sequence from smear positive 383 
samples which failed to grow. Level of smear positivity is shown, with the remaining 384 
being smear negative. 385 
Figure 3: Heteroresistance in gyrA in patient 10. R= resistant allele with suffix 386 
indicating codon position, S= absence of resistant allele. 387 
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Table 1: Resistance phenotype and genotype of matched pairs. R= a mutation exists 388 
at greater than 10%. Low R= mutation in codon 306 of embB gene which is thought 389 
to confer low level resistance to ethambutol. Rif = rifampicin, Inh= isoniazid, Emb = 390 
ethambutol, Pza = pyrazinamide, Str = streptomycin, Ofl= Ofloxacin 391 
(fluoroquinolones), Pas = para-Aminosalicylic acid, Amg = aminoglycosides, Thi = 392 
thionamides. 393 
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Supplementary table 1: Available details of samples sequenced in this study. 
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Supplementary Figure 1: Flow diagram for preparation of M. tb samples for 
enrichment based WGS from receipt of extracted genomic DNA to final data report.  
Times given are based on 16 samples processed manually or 96 samples processed 
using automation; Enrichment- we have seen comparable data from 16h vs 24h 
enrichment; MiSeq times are depending on MiSeq cartridge and chemistry used 
(2x75bp v3 run = ~16h, 2x300bp v3 run = ~68h) 
 
 
 
 
 
 
Supplementary Figure 2: Comparison of sequence results from culture with and 
without enrichment for two samples. 
 
 
Supplementary Figure 3: Coverage plot of enriched sputum sample MTB-40 
mapped against H37Rv. Maximum point on graph is 568.6 and minimum is 0. X axis 
indicates base position along the genome. Adapted from image generated using 
Artemis (Carver et. al. 2012 http://www.sanger.ac.uk/resources/software/artemis/). 
 
 
 
 
 
 
 
Supplementary Figure 4: Maximum likelihood tree of all samples where at least 1x 
depth of coverage was obtained. Clade support is indicated by number of bootstrap 
replicates (out of 100). Scale bar represents substitutions per site. Some samples 
were identified as being on long branches or positioned close to nodes. Further 
investigation revealed that they all had at least 10% missing data in the SNP 
alignment, due to low coverage or heterozygosity, so could not be placed accurately 
on the tree. The samples indicated in red were removed from the final maximum 
likelihood tree shown in Supplementary Figure 3. 
 
Supplementary Figure 5: Maximum likelihood tree of 45 samples that had high 
coverage and could be accurately placed on the tree (see Supplementary Figure 2). 
Clade support is indicated by number of bootstrap replicates (out of 100). The tree 
was constructed using RAxML. Scale bar represents substitutions per site. 
 
 
Supplementary Figure 6: Deletion of pncA and surrounding genes identified in 
patient 7. Coverage plot is shown in grey. 
 
 
 
Supplementary table 2: Resistance genotypes identified in this study that passed 
all quality criteria and were found at greater than 10% frequency. The position of the 
mutation identified in column D refers to H37Rv (AL123456.3). Support on the 
forward, reverse and from individual nucelotides is shown. Any variants that didn’t 
match the observed phenotype were cross-references against the literature, and are 
discussed in the main text. 
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